JP2007530703A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007530703A5 JP2007530703A5 JP2007506442A JP2007506442A JP2007530703A5 JP 2007530703 A5 JP2007530703 A5 JP 2007530703A5 JP 2007506442 A JP2007506442 A JP 2007506442A JP 2007506442 A JP2007506442 A JP 2007506442A JP 2007530703 A5 JP2007530703 A5 JP 2007530703A5
- Authority
- JP
- Japan
- Prior art keywords
- formula
- pharmaceutical composition
- disease
- neuropathy
- damaged
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 150000001875 compounds Chemical class 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 208000016192 Demyelinating disease Diseases 0.000 claims 2
- 102000006386 Myelin Proteins Human genes 0.000 claims 2
- 108010083674 Myelin Proteins Proteins 0.000 claims 2
- 208000028389 Nerve injury Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 210000005012 myelin Anatomy 0.000 claims 2
- 230000008764 nerve damage Effects 0.000 claims 2
- 210000004498 neuroglial cell Anatomy 0.000 claims 2
- 201000001119 neuropathy Diseases 0.000 claims 2
- 230000007823 neuropathy Effects 0.000 claims 2
- 208000033808 peripheral neuropathy Diseases 0.000 claims 2
- 208000020431 spinal cord injury Diseases 0.000 claims 2
- 201000011452 Adrenoleukodystrophy Diseases 0.000 claims 1
- 208000010693 Charcot-Marie-Tooth Disease Diseases 0.000 claims 1
- 208000035895 Guillain-Barré syndrome Diseases 0.000 claims 1
- 102000009030 Member 1 Subfamily D ATP Binding Cassette Transporter Human genes 0.000 claims 1
- 108010049137 Member 1 Subfamily D ATP Binding Cassette Transporter Proteins 0.000 claims 1
- 206010049567 Miller Fisher syndrome Diseases 0.000 claims 1
- 102100026784 Myelin proteolipid protein Human genes 0.000 claims 1
- 208000003435 Optic Neuritis Diseases 0.000 claims 1
- 208000017493 Pelizaeus-Merzbacher disease Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 201000002491 encephalomyelitis Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US55853304P | 2004-04-01 | 2004-04-01 | |
| US60/558,533 | 2004-04-01 | ||
| PCT/US2005/010371 WO2005097098A2 (en) | 2004-04-01 | 2005-03-29 | Use of ppr delta agonists for treating demyelinating diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007530703A JP2007530703A (ja) | 2007-11-01 |
| JP2007530703A5 true JP2007530703A5 (enExample) | 2008-05-08 |
Family
ID=34977094
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007506442A Abandoned JP2007530703A (ja) | 2004-04-01 | 2005-03-29 | Ｍｓおよびその他の脱髄疾患を治療するためのペルオキシソーム増殖因子活性化受容体デルタアゴニストの使用 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20070149580A1 (enExample) |
| EP (1) | EP1737440A2 (enExample) |
| JP (1) | JP2007530703A (enExample) |
| KR (1) | KR20060134191A (enExample) |
| CN (1) | CN1950077A (enExample) |
| AU (1) | AU2005231358A1 (enExample) |
| BR (1) | BRPI0509540A (enExample) |
| CA (1) | CA2561159A1 (enExample) |
| IL (1) | IL178165A0 (enExample) |
| MA (1) | MA28561B1 (enExample) |
| MX (1) | MXPA06011218A (enExample) |
| NO (1) | NO20064985L (enExample) |
| RU (1) | RU2006138495A (enExample) |
| SG (1) | SG138623A1 (enExample) |
| WO (1) | WO2005097098A2 (enExample) |
| ZA (1) | ZA200607850B (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005105726A1 (en) | 2004-05-05 | 2005-11-10 | Novo Nordisk A/S | Novel compounds, their preparation and use |
| EP1745014B1 (en) | 2004-05-05 | 2011-07-06 | High Point Pharmaceuticals, LLC | Novel compounds, their preparation and use |
| EP2298742B1 (en) | 2005-06-30 | 2014-01-08 | High Point Pharmaceuticals, LLC | phenoxy acetic acids as PPAR delta activators |
| CN101336113B (zh) * | 2005-11-28 | 2015-07-29 | 千寿制药株式会社 | 包括ppar激动剂的药物 |
| EP2386540A1 (en) | 2005-12-22 | 2011-11-16 | High Point Pharmaceuticals, LLC | Novel compounds, their preparation and use |
| CA2645719A1 (en) | 2006-03-09 | 2007-09-13 | High Point Pharmaceuticals, Llc | Compounds that modulate ppar activity, their preparation and use |
| CA2727373A1 (en) | 2008-06-09 | 2009-12-17 | Sanofi-Aventis | Annelated n-heterocyclic sulfonamides with oxadiazolone headgroup, processes for their preparation and their use as pharmaceuticals |
| US8716317B2 (en) | 2008-06-09 | 2014-05-06 | Sanofi | Sulfonamides with heterocycle and oxadiazolone headgroup, processes for their preparation and their use as pharmaceuticals |
| US20120301463A1 (en) | 2009-09-30 | 2012-11-29 | President And Fellows Of Harvard College | Methods for Modulation of Autophagy Through the Modulation of Autophagy-Enhancing Gene Products |
| US20130117868A1 (en) | 2009-12-17 | 2013-05-09 | Sanofi | Animal Model Expressing Luciferase under Control of the Myelin Basic Protein Promoter (MBP-luci) and Use of the Model for Bioluminescence In Vivo Imaging |
| DK2675893T3 (en) * | 2011-02-18 | 2019-04-15 | Scripps Research Inst | Directed differentiation of oligodendrocyte precursor cells into a myelinating cell fate |
| WO2015035171A1 (en) | 2013-09-09 | 2015-03-12 | High Point Pharmaceuticals, Llc | Use of a ppar-delta agonist for treating muscle atrophy |
| WO2021092279A1 (en) * | 2019-11-06 | 2021-05-14 | Board Of Regents, The University Of Texas System | Methods for the treatment of dysmyelinating/demyelinating diseases |
| WO2023147309A1 (en) | 2022-01-25 | 2023-08-03 | Reneo Pharmaceuticals, Inc. | Use of ppar-delta agonists in the treatment of disease |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997028149A1 (en) * | 1996-02-02 | 1997-08-07 | Merck & Co., Inc. | Method for raising hdl cholesterol levels |
| GB9914977D0 (en) * | 1999-06-25 | 1999-08-25 | Glaxo Group Ltd | Chemical compounds |
| AU2001288271A1 (en) * | 2000-08-17 | 2002-02-25 | Harrihar A. Pershadsingh | Methods for treating inflammatory diseases |
| GB0024361D0 (en) * | 2000-10-05 | 2000-11-22 | Glaxo Group Ltd | Medicaments |
| GB0024362D0 (en) * | 2000-10-05 | 2000-11-22 | Glaxo Group Ltd | Medicaments |
| WO2004082621A2 (en) * | 2003-03-15 | 2004-09-30 | Bethesda Pharmaceuticals, Inc. | Novel ppar agonists, pharmaceutical compositions and uses thereof |
| WO2004093910A1 (ja) * | 2003-04-22 | 2004-11-04 | Astellas Pharma Inc. | ＰＰＡＲδアゴニストによる脳神経変性疾患治療剤 |
-
2005
- 2005-03-29 JP JP2007506442A patent/JP2007530703A/ja not_active Abandoned
- 2005-03-29 BR BRPI0509540-9A patent/BRPI0509540A/pt not_active IP Right Cessation
- 2005-03-29 RU RU2006138495/14A patent/RU2006138495A/ru not_active Application Discontinuation
- 2005-03-29 WO PCT/US2005/010371 patent/WO2005097098A2/en not_active Ceased
- 2005-03-29 CA CA002561159A patent/CA2561159A1/en not_active Abandoned
- 2005-03-29 SG SG200800123-2A patent/SG138623A1/en unknown
- 2005-03-29 MX MXPA06011218A patent/MXPA06011218A/es not_active Application Discontinuation
- 2005-03-29 EP EP05729215A patent/EP1737440A2/en not_active Withdrawn
- 2005-03-29 CN CNA2005800148506A patent/CN1950077A/zh active Pending
- 2005-03-29 KR KR1020067022955A patent/KR20060134191A/ko not_active Withdrawn
- 2005-03-29 AU AU2005231358A patent/AU2005231358A1/en not_active Abandoned
-
2006
- 2006-09-18 IL IL178165A patent/IL178165A0/en unknown
- 2006-09-19 ZA ZA200607850A patent/ZA200607850B/xx unknown
- 2006-09-26 US US11/535,240 patent/US20070149580A1/en not_active Abandoned
- 2006-10-31 MA MA29427A patent/MA28561B1/fr unknown
- 2006-10-31 NO NO20064985A patent/NO20064985L/no not_active Application Discontinuation